IL-2 is a powerful growth factor for T cells. New work shows that immune checkpoint blockade depends upon the presence of IL-2, and that mesenchymal stem cells can be efficiently engineered to safely deliver it directly in advanced tumours to rescue CD8+ T cell responsiveness to anti-PD-L1 antibody treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lanitis, E., Dangaj, D., Irving, M. & Coukos, G. Ann. Oncol. 28, xii18–xii32 (2017).
Ross, S. H. & Cantrell, D. A. Annu. Rev. Immunol. 36, 411–433 (2018).
Rosenberg, S. A. J. Immunol. 192, 5451–5458 (2014).
Bae, J. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-022-01024-5 (2022).
Andreatta, M. et al. Nat. Commun. 12, 2965 (2021).
Mo, F. et al. Nature 597, 544–548 (2021).
Sun, Z. et al. Nat. Commun. 10, 3874 (2019).
Levin, A. M. et al. Nature 484, 529–533 (2012).
Mott, H. R. et al. J. Mol. Biol. 247, 979–994 (1995).
Westerman, K. A. & Leboulch, P. Proc. Natl Acad. Sci. USA 93, 8971–8976 (1996).
Li, X. et al. Nat. Commun. 10, 3251 (2019).
Miller, B. C. et al. Nat. Immunol. 20, 326–336 (2019).
Guo, Y. et al. Nat. Immunol. 22, 746–756 (2021).
Krishna, S. et al. Science 370, 1328–1334 (2020).
Herrera, F. G. et al. Cancer Discov. 12, 108–133 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.C. has received grants or research support from, or is coinvestigator in clinical trials by, Bristol-Myers Squibb, Celgene, Boehringer Ingelheim, Roche, Tigen Pharma, Iovance and Kite. The Lausanne University Hospital (CHUV) has received honoraria for advisory services G.C. has provided to AstraZeneca AG, Bristol-Myers Squibb SA, F. Hoffmann-La Roche AG, MSD Merck AG and Geneos Therapeutics. G.C. has patents in the domain of antibodies and vaccines targeting the tumour vasculature as well as technologies related to T cell expansion and engineering for T cell therapy. G.C. has received royalties from the University of Pennsylvania. The three co-authors are included in an intellectual property filing regarding an IL-2 variant.
Rights and permissions
About this article
Cite this article
Irving, M., Ortiz-Miranda, Y. & Coukos, G. IL-2 engineered MSCs rescue T cells in tumours. Nat Cell Biol 24, 1689–1691 (2022). https://doi.org/10.1038/s41556-022-01029-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-022-01029-0
